Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, October 17, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Yigal Nochomovitz Maintained (ALDX) at Strong Buy with Decreased Target to $8 on, Oct 17th, 2023
Yigal Nochomovitz of Citigroup, Maintained "Aldeyra Therapeutics, Inc." (ALDX) at Strong Buy with Decreased Target from $25 to $8 on, Oct 17th, 2023.
Yigal has made no other calls on ALDX in the last 4 months.
There is 1 other peer that has a rating on ALDX. Out of the 1 peers that are also analyzing ALDX, 0 agree with Yigal's Rating of Hold.
This is the rating of the analyst that currently disagrees with Yigal
- Matthew Caufield of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $15 on, Friday, June 30th, 2023
